Clarification of Non-FDA Approved CPAP Devices During PHE

Published in Government Relations on November 05, 2021

VGM recently received this question:

Is it possible to bill a Class II Medical Device (CPAP) to insurance without a 510(k) clearance?  In the context of the pandemic, supply chain shortages, and the Philips Respironics recall, we are looking at alternative vendors for our CPAP product line. The device in question has an emergency FDA authorization but has not received a 501(k) clearance at this time. The vendor has no realistic idea of the potential risk we may incur, and we are looking for guidance regarding this time-sensitive situation.

To begin, let’s define a 510(k) clearance:

Section 510(k) of the Food, Drug, and Cosmetic Act requires device manufacturers who must register, to notify the FDA of their intent to market a medical device at least 90 days in advance. This is known as Premarket Notification - also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories. Thus, "new" devices that have not been classified can be properly identified. Specifically, medical device manufacturers are required to submit a premarket notification if they intend to introduce a device into commercial distribution for the first time or reintroduce a device that will be significantly changed or modified to the extent that its safety or effectiveness could be affected.

Readers may be aware that during a public health emergency, the FDA can use its Emergency Use Authorization (EUA) authority to allow the use of unapproved medical products, or unapproved uses of approved medical products, to diagnose, treat, or prevent serious or life-threatening diseases when certain criteria are met, including that there are no adequate, approved, and available alternatives.

Before the FDA can issue a EUA, the Secretary of Health and Human Services must make a declaration of emergency or threat justifying authorization of emergency use for a product.

How do I know if the FDA has issued a EUA for a medical device? 

The FDA has a website that includes medical device EUAs. Go to Emergency Use Authorizations for Medical Devices. This page lists current EUAs issued for medical devices during the COVID-19 pandemic as well as EUAs issued during previous public health emergencies.

The FDA has released its Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices.

The Secretary of HHS has declared that circumstances exist justifying the authorization of emergency use of (among others) “personal respiratory protective devices” (March 2, 2020), and other medical devices, including alternative products used as medical devices (March 24, 2020), for use during the COVID-19 outbreak pursuant to section 564 of the Act and subject to the terms of any authorization issued under that section.

Do “personal respiratory protective devices” and/or “other medical devices” include CPAP?

The EUA link noted above includes categories:

  • Respiratory Assist Devices EUAs
  • Ventilators and Ventilator Accessories EUAs
  • Other Medical Device EUAs

The first category (Respiratory Assist Devices) includes these EUAs; note there is no allowance for CPAP (nor Bi-level1) devices   

The second (Ventilators and Ventilator Accessories) includes these EUAs.  This EUA authorizes the emergency use of “certain ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors, and ventilator accessories” that the FDA determines meet specified criteria for safety, performance, and labeling. The devices that are eligible for inclusion under the EUA are those that are not currently marketed in the U.S., or those that are currently marketed in the U.S. but a modification is made to the device that would trigger the requirement that a manufacturer submit a new premarket notification (510(k)) to the FDA, as discussed in the agency's Ventilator Enforcement Policy.

This page includes a list of authorized ventilator, ventilator tubing connector, and ventilator accessory to the list of authorized products in this Umbrella EUA during the COVID-19 public health emergency.

This same page includes:

  • The EUA Letter of Authorization
  • Facts Sheets for Healthcare Providers
  • Facts Sheets for Patients
  • Appendix A: Criteria for Safety, Performance, and Labeling
  • Appendix B: Authorized Ventilators, Ventilator Tubing Connectors, and Ventilator Accessories

The third category “Other Medical Devices” includes no inclusion of CPAP or bi-level devices.

Accordingly, there exists no exception for non-FDA-approved CPAP devices. They may not be billed to Medicare, Medicaid, or commercial insurance carriers. There are allowances for certain non-invasive ventilators and accessories. 

In summary, the process of the 510(k) is demonstrating to the FDA that the medical device is safe and effective for use and meets the medical device status. The CMS Quality Standards for DMEPOS, which are encompassed in accreditation requirements, requires suppliers of these services to make sure the medical equipment is safe and effective for beneficiary use.

Please review closely the information provided by the U.S. Food and Drug Administration via the links included within this update.

Questions?  Please contact Mark Higley, Vice-President of Regulatory Affairs, at mark.higley@vgm.com or 319.504.9515 or Ronda Buhrmester, Sr Director of Payer Relations & Reimbursement at ronda.buhrmester@vgm.com or 217-493-5440.


1 Unless used as “Ventilator, Continuous, Minimal Ventilatory Support”; see complete product listings here.


TAGS

  1. phe
  2. regulatory

From Our Experts

You Got the Contract! …NOW WHAT?! A Short Series thumbnail You Got the Contract! …NOW WHAT?! A Short Series Congratulations! You FINALLY got the contract you've been working so hard on all these months. Now that you have it, what are the critical next steps you need to take to maintain and implement the contract and generate ROI? Welcome to the first of a short series of articles to help you accomplish just that. NAAOP Hosts First Ever In-Person Legislative Fly-In thumbnail NAAOP Hosts First Ever In-Person Legislative Fly-In Last week, 33 stakeholders, advocates, and leaders from around the O&P industry convened at the offices of Powers Pyles Sutter & Verville PC in Washington, D.C., as part of The National Association for the Advancement of Orthotics and Prosthetics's (NAAOP) first ever in-person legislative fly-in. Co-sponsored by OPGA, the fly-in kicked off with an in-depth discussion and strategy session surrounding several legislative priorities affecting O&P providers and patients. VGM Government Relations Unveils Grassroots Advocacy Toolkit to Empower DME Champions of Change thumbnail VGM Government Relations Unveils Grassroots Advocacy Toolkit to Empower DME Champions of Change The VGM Government Relations team is proud to announce the launch of its Grassroots Advocacy Toolkit, thoughtfully crafted to support durable medical equipment (DME) professionals, caregivers, industry partners, and patient advocates in advancing legislative initiatives that impact home medical equipment and services. Featuring Two Champions Of Change: Robert Beard of YD Home Medical & Rob Minicucci Jr. of Health System Services thumbnail Featuring Two Champions Of Change: Robert Beard of YD Home Medical & Rob Minicucci Jr. of Health System Services Today, we're proud to spotlight two outstanding durable medical equipment (DME) champions whose advocacy efforts are making a meaningful difference: Robert Beard of YD Home Medical of Alabama and Rob Minicucci Jr. of Health System Services of New York. These individuals took time out of their busy schedules to personally connect with elected officials, demonstrating how local action can spark national change. Survey: Share Your Thoughts on Proposed Accreditation Rule Changes thumbnail Survey: Share Your Thoughts on Proposed Accreditation Rule Changes CQRC, VGM, and AAHomecare are requesting your feedback on a new proposed rule that could significantly impact accreditation procedures. Under the proposal, accreditation organizations would be required to conduct site visits every year—a major shift from the current once-every-three-years schedule. WEBINAR: Navigating New CMS Guidelines: Unlocking Opportunities in NIPPV and RAD Coverage for COPD Care thumbnail WEBINAR: Navigating New CMS Guidelines: Unlocking Opportunities in NIPPV and RAD Coverage for COPD Care The Centers for Medicare & Medicaid Services (CMS) has revised the NCD for Noninvasive Positive Pressure Ventilation (NIPPV) in the home setting for treating Chronic Respiratory Failure (CRF) due to Chronic Obstructive Pulmonary Disease (COPD). The changes aim to establish clear coverage policies for devices such as Respiratory Assist Devices (RADs) and home mechanical ventilators (HMVs), potentially expanding access to these critical therapies for eligible patients. Adapting to new CMS guidelin Bipartisan Medicare O&P Bill Introduced thumbnail Bipartisan Medicare O&P Bill Introduced In a timely move ahead of next week's NAAOP Legislative Fly-In, a bipartisan group of lawmakers introduced the Medicare Orthotics and Prosthetics Patient-Centered Care Act, a bill aimed at improving access to high-quality orthotic and prosthetic care for Medicare beneficiaries. The Patient-Centered Care Act seeks to address critical gaps in Medicare coverage for orthotic and prosthetic (O&P) services. Under current rules, beneficiaries may receive devices without the necessary clinical services Proposed Rule Suggests Significant Change To Accreditation Process thumbnail Proposed Rule Suggests Significant Change To Accreditation Process The recently released proposed rule CMS-1828-P contains a significant change that could reshape how suppliers navigate accreditation. The rule proposes a major change that would require suppliers to be surveyed and reaccredited annually instead of the current three (3) year cadence. This proposal raises substantial questions about both operational feasibility and cost implications.